NYSE:NGVT

Ingevity Stock Forecast, Price & News

$69.96
-1.43 (-2.00 %)
(As of 09/21/2021 03:57 PM ET)
Add
Compare
Today's Range
$69.95
$71.16
50-Day Range
$71.39
$87.31
52-Week Range
$47.11
$89.55
Volume3,190 shs
Average Volume238,898 shs
Market Capitalization$2.76 billion
P/E Ratio13.40
Dividend YieldN/A
Beta2.21
30 days | 90 days | 365 days | Advanced Chart
Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.


Ingevity logo

About Ingevity

Ingevity Corp. engages in the manufacture of specialty chemicals and carbon materials. It operates through the following segments: Performance Chemicals and Performance Materials. The Performance Materials segment consists of automotive technologies and process purifications product families. Automotive technologies produces automotive carbon products used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. Process purifications produce a number of activated carbon products for food, water, beverage and chemical purification applications. The Performance Chemicals segment primarily addresses applications in three product families: pavement technologies, oilfield technologies, and industrial specialties. The company was founded on March 27, 2015 and is headquartered in North Charleston, SC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.41 out of 5 stars

Basic Materials Sector

61st out of 225 stocks

Chemicals & Allied Products Industry

7th out of 20 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ingevity (NYSE:NGVT) Frequently Asked Questions

Is Ingevity a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity
or view top-rated stocks.

What stocks does MarketBeat like better than Ingevity?

Wall Street analysts have given Ingevity a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ingevity wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ingevity?

Ingevity saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 839,600 shares, a decrease of 17.7% from the July 29th total of 1,020,000 shares. Based on an average daily volume of 206,700 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.2% of the company's shares are short sold.
View Ingevity's Short Interest
.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Tuesday, October 19th 2021.
View our earnings forecast for Ingevity
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) announced its earnings results on Wednesday, July, 28th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.34. The firm had revenue of $358.40 million for the quarter, compared to the consensus estimate of $331.55 million. Ingevity had a net margin of 16.00% and a trailing twelve-month return on equity of 37.34%.
View Ingevity's earnings history
.

How has Ingevity's stock been impacted by Coronavirus?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NGVT shares have increased by 81.5% and is now trading at $70.41.
View which stocks have been most impacted by COVID-19
.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.33 billion.

What price target have analysts set for NGVT?

3 brokerages have issued 12 month price targets for Ingevity's stock. Their forecasts range from $85.00 to $112.00. On average, they anticipate Ingevity's share price to reach $97.33 in the next year. This suggests a possible upside of 38.2% from the stock's current price.
View analysts' price targets for Ingevity
or view top-rated stocks among Wall Street analysts.

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • John C. Fortson, President, CEO, Treasurer & Director
  • Marty Heyne, Senior Vice President-Operations
  • Mary Dean Hall, Chief Financial Officer & Executive Vice President
  • Mike Smith, EVP, President-Strategy & Business Development
  • Stacy Lancaster Cozad, Secretary, Vice President & General Counsel

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ingevity's key competitors?

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), The Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.15%), Vanguard Group Inc. (10.02%), Boston Partners (5.89%), State Street Corp (3.08%), LSV Asset Management (2.81%) and Broad Bay Capital Management LP (2.51%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends for Ingevity
.

Which institutional investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Franklin Resources Inc., Broad Bay Capital Management LP, State Street Corp, Rice Hall James & Associates LLC, Southernsun Asset Management LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Ingevity
or view top insider-selling stocks.

Which institutional investors are buying Ingevity stock?

NGVT stock was acquired by a variety of institutional investors in the last quarter, including Teacher Retirement System of Texas, Maple Rock Capital Partners Inc., Millennium Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Castleark Management LLC, Calamos Advisors LLC, Primecap Management Co. CA, and Invesco Ltd.. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson.
View insider buying and selling activity for Ingevity
or or view top insider-buying stocks.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $70.41.

How much money does Ingevity make?

Ingevity has a market capitalization of $2.78 billion and generates $1.22 billion in revenue each year. The company earns $181.40 million in net income (profit) each year or $4.88 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,750 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

Where are Ingevity's headquarters?

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The company can be reached via phone at (844) 643-8489 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.